STAT Plus: Bernie Sanders targets ‘outrageously high price’ of Ozempic
Biogen
Biogen Inc., of Cambridge, Mass., is a multinational biotechnology giant offering products related to depression, Alzheimer’s disease, multiple sclerosis, hemophilia and leukemia. Here’s the latest Biogen news.
Latest
STAT Plus: A spending frenzy on obesity drugs
STAT Plus: Looking for signs of growth in Biogen’s earnings
STAT Plus: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025
STAT Plus: The biotech scoreboard for the second quarter: 32 stock-moving events to watch
Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon
STAT Plus: Years after a polarizing approval, Biogen walks away from Aduhelm
STAT Plus: Biogen shutters digital health group, nixes Apple study, as part of cost cuts
All Coverage
advertisement
